TrialJournal for immunotherapy of cancer2024

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.

Shengxiang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.